Experimental drug VVZ-2471 gets first safety check in humans

NCT ID NCT07531316

Not yet recruiting Knowledge-focused Sponsor: Virginia Commonwealth University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This early-stage trial will test whether an experimental drug called VVZ-2471 is safe and tolerable in 60 healthy adults aged 18 to 65 who show high impulsivity. Participants will take either the drug or a placebo twice daily for 14 days. The results will help researchers design future studies for people with substance use disorders.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VVZ-2471 (experimental medication)
What this could lead to: If successful, this study could pave the way for larger trials testing whether VVZ-2471 helps people with substance use disorders.
What could go wrong: This is an early Phase 1 safety study in healthy volunteers, not patients. It is not designed to test effectiveness, and the medication may not work or may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY CONTROLS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY CONTROLS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

VCU Institute for Drug and Alcohol Studies

Richmond, Virginia, 23219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.